Clinical trial
Study Evaluating rFIX; BeneFIX® in Hemophilia B
NCT00093171 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00093171 |
|---|---|
| Title | Study Evaluating rFIX; BeneFIX® in Hemophilia B |
| Official title | An Open-label Safety and Efficacy Study of Recombinant Human Factor IX (rFIX; BeneFIX®) in Previously Treated Patients (PTPs) With Hemophilia B (FIX:C ≤2%) |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hemophilia B |
| Intervention type | Drug |
| Interventions | rFIX |
| Enrollment | 23 |
| Primary completion | May 1, 2005 |
| Completion | May 1, 2005 |
| First posted | Oct 7, 2004 |
| Last update posted | Aug 21, 2009 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: